Anticorps Monoclonal anti-Amphiregulin
Amphiregulin Monoclonal Antibody for WB, IHC, ELISA
Hôte / Isotype
Mouse / IgG1
Réactivité testée
Humain, porc, rat et plus (1)
Applications
WB, IHC, IF, ELISA
Conjugaison
Non conjugué
CloneNo.
1A1G9
N° de cat : 66433-1-Ig
Synonymes
Galerie de données de validation
Applications testées
| Résultats positifs en WB | cellules A549, cellules MCF-7, tissu cérébral de porc, tissu cérébral de rat |
| Résultats positifs en IHC | tissu de cancer du pancréas humain, tissu de cancer du côlon humain il est suggéré de démasquer l'antigène avec un tampon de TE buffer pH 9.0; (*) À défaut, 'le démasquage de l'antigène peut être 'effectué avec un tampon citrate pH 6,0. |
Dilution recommandée
| Application | Dilution |
|---|---|
| Western Blot (WB) | WB : 1:1000-1:6000 |
| Immunohistochimie (IHC) | IHC : 1:50-1:500 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, check data in validation data gallery | |
Applications publiées
| WB | See 2 publications below |
| IHC | See 1 publications below |
| IF | See 2 publications below |
Informations sur le produit
66433-1-Ig cible Amphiregulin dans les applications de WB, IHC, IF, ELISA et montre une réactivité avec des échantillons Humain, porc, rat
| Réactivité | Humain, porc, rat |
| Réactivité citée | Humain, souris |
| Hôte / Isotype | Mouse / IgG1 |
| Clonalité | Monoclonal |
| Type | Anticorps |
| Immunogène | Amphiregulin Protéine recombinante Ag8907 |
| Nom complet | amphiregulin |
| Masse moléculaire calculée | 252 aa, 28 kDa |
| Poids moléculaire observé | 50 kDa, 37 kDa |
| Numéro d’acquisition GenBank | BC009799 |
| Symbole du gène | Amphiregulin/AREG |
| Identification du gène (NCBI) | 374 |
| Conjugaison | Non conjugué |
| Forme | Liquide |
| Méthode de purification | Purification par protéine G |
| Tampon de stockage | PBS with 0.02% sodium azide and 50% glycerol |
| Conditions de stockage | Stocker à -20°C. Stable pendant un an après l'expédition. L'aliquotage n'est pas nécessaire pour le stockage à -20oC Les 20ul contiennent 0,1% de BSA. |
Informations générales
Amphiregulin (AREG) is one of the ligands of the epidermal growth factor receptor (EGFR). AREG plays a central role in mammary gland development and branching morphogenesis in organs and is expressed both in physiological and in cancerous tissues. The AREG protein is synthesized as a 252-amino acid transmembrane precursor, pro-AREG. At the plasma membrane, pro-AREG is subjected to sequential proteolytic cleavages within its ectodomain and is then released as the soluble AREG protein. Depending on the cell type and microenvironment, AREG can be produced in multiple cellular and mature forms using alternative pro-AREG cleavage sites and glycosylation motifs. Post-translastional modfications of 50-kDa pro-AREG produces a major soluble 43-kDa form, 28-, 26-, 16-kDa membrane anchored forms, and soluble 21-, 19-, and 9-kDa forms (PMID: 9642297).
Protocole
| Product Specific Protocols | |
|---|---|
| WB protocol for Amphiregulin antibody 66433-1-Ig | Download protocol |
| IHC protocol for Amphiregulin antibody 66433-1-Ig | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
| Species | Application | Title |
|---|---|---|
Cell Rep Med Tumor-associated monocytes promote mesenchymal transformation through EGFR signaling in glioma | ||
J Invest Dermatol LPCAT1 promotes cutaneous squamous cell carcinoma via EGFR-mediated AKT/p38MAPK signaling pathways. | ||
Int J Biol Sci CD9 regulates keratinocyte migration by negatively modulating the sheddase activity of ADAM17. | ||
Nat Commun A single cell atlas of frozen shoulder capsule identifies features associated with inflammatory fibrosis resolution | ||
Cell Death Dis TLR9 activation in large wound induces tissue repair and hair follicle regeneration via γδT cells | ||
Cells AREG Upregulation in Cancer Cells via Direct Interaction with Cancer-Associated Fibroblasts Promotes Esophageal Squamous Cell Carcinoma Progression Through EGFR-Erk/p38 MAPK Signaling |







